Black Rock Inc. Tyra Biosciences, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,418,855 shares of TYRA stock, worth $22.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,418,855

Previous 1,044,225 35.88%

Holding current value

$22.5 Million

Previous $17.1 Million 32.48%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$14.45 - $20.22 $5.41 Million - $7.58 Million	374,630 Added 35.88%	1,418,855 $22.7 Million
Q1 2024 May 10, 2024	BUY	$11.61 - $20.0 $919,407 - $1.58 Million	79,191 Added 8.21%	1,044,225 $17.1 Million
Q4 2023 Feb 13, 2024	BUY	$11.01 - $14.95 $755,087 - $1.03 Million	68,582 Added 7.65%	965,034 $13.4 Million
Q3 2023 Nov 13, 2023	BUY	$13.15 - $16.08 $73,903 - $90,369	5,620 Added 0.63%	896,452 $12.3 Million
Q2 2023 Aug 11, 2023	BUY	$11.99 - $17.51 $2.69 Million - $3.92 Million	223,947 Added 33.58%	890,832 $15.2 Million
Q1 2023 May 12, 2023	BUY	$6.85 - $16.22 $80,788 - $191,298	11,794 Added 1.8%	666,885 $10.7 Million
Q4 2022 Feb 13, 2023	BUY	$5.68 - $8.81 $187,400 - $290,668	32,993 Added 5.3%	655,091 $4.98 Million
Q3 2022 Nov 14, 2022	SELL	$6.61 - $12.42 $57,883 - $108,761	-8,757 Reduced 1.39%	622,098 $5.47 Million
Q2 2022 Aug 12, 2022	BUY	$5.26 - $11.19 $250,475 - $532,856	47,619 Added 8.16%	630,855 $4.51 Million
Q1 2022 May 12, 2022	SELL	$10.03 - $14.09 $53,459 - $75,099	-5,330 Reduced 0.91%	583,236 $6.24 Million
Q4 2021 Feb 10, 2022	BUY	$12.23 - $31.35 $7.2 Million - $18.5 Million	588,566 New	588,566 $8.28 Million

Others Institutions Holding TYRA

# of Institutions

Shares Held

43.5M

Call Options Held

353K

Put Options Held

1.1K

View Full List

About Tyra Biosciences, Inc.

Ticker TYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,973,600
Market Cap $664M
Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...

More about TYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account